ALX Oncology, a Bay Area biotech firm currently running clinical trials for its anticancer therapy, announced Wednesday that it’s laying off about 30% of its staff. ALX shared the news in a ...

Fresh from a $105 million third-round financing earlier this month, ALX Oncology has won two FDA fast-track designations for its lead immuno-oncology drug. The Irish-American biotech picked up the ...